Trial Profile
A Multi-Center, Open-Label, Two-Period Cross-Over, Patient-Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox) Tablets in Thalassemia Patients With Inadequate Response to Standard Chelation Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Thalassaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors AustinPx; DisperSol Technologies
- 31 Jan 2022 Status changed from recruiting to completed.
- 10 Jun 2021 Planned End Date changed from 28 Mar 2021 to 30 Oct 2021.
- 10 Jun 2021 Planned primary completion date changed from 28 Feb 2021 to 30 Sep 2021.